Similarly, TGF-β inhibitors may reverse T cell exclusion due to cancer-associated fibroblast (CAF)-mediated TGF-β signaling in addition to reducing suppressive immune cells and their activity [134,152,170]. The gene discussed is TGFB1; the disease is cancer.